This site is intended for healthcare professionals

Opdivo in combination with Cabometyx shows sustained survival and response rate benefits as first-line treatment for advanced renal cell carcinoma in the Phase III CheckMate -9ER trial- BMS + Exelixis, Inc.

Read time: 2 mins
Last updated:28th Jun 2021
Published:10th Feb 2021
Condition: Renal Cell Carcinoma
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest